
Assessing breast MRI scans, pathology and clinical data, the AI-powered TumorSight Risk software reportedly provides five- and 10-year risk for breast cancer recurrence for women with HR+, HER2-negative stage I-IIIA breast cancer.
ECR attendees glimpsed a workstation in the Sectra booth that could be the forerunner of a new way of handling and interpreting data from medical imaging scans. Greg Freiherr has the story from the exhibit floor of ECR 2009.
ECR attendees glimpsed a workstation in the Sectra booth that could be the forerunner of a new way of handling and interpreting data from medical imaging scans. Greg Freiherr has the story from the exhibit floor of ECR 2009.






